Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Harmony Biosciences Holdings Inc.
HRMY | US
34.95
USD-0.46
-1.30%
HRMY | US
About Harmony Biosciences Holdings Inc.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
34.95
Open
35.37
High
35.44
Low
34.63
Harmony Biosciences Holdings Inc. a commercial-stage pharmaceutical company focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant) a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II Inc. and changed its name to Harmony Biosciences Holdings Inc. in February 2020. Harmony Biosciences Holdings Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting Pennsylvania.
View LessHRMY | US
Risk
50.4
Sharpe
1.04
Luna's Score
46/100
Recommendation
Hold
Luna says (HRMY | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Strong Revenue Growth (> 10%)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Smallcap (300M - 2B USD)
High Short percentage (> 15%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
30.0%1 month
50.4%3 months
40.7%6 months
38.1%Returns
Fundamental Ratios
PE
18.16
Fwd. PE
8.79
Price to book
3.69
Debt to equity
0.41
Debt to assets
0.26
Ent. to EBITDA
8.69
Ent. to rev.
2.78
PEG
-
Other Fundamentals
EBITDA
202.50M
MarketCap
1.99B
MarketCap(USD)
1.99B
Div. yield
-
Op. margin
12.36
Erngs. growth
-64.30
Rev. growth
28.80
Ret. on equity
22.47
Short ratio
17.70
Short perc.
67.07
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
2.78
Range1M
7.22
Range3M
10.72
Volumes: Market Activity
Rel. volume
1.25
Price X volume
25.58M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 8.69 | - | Expensive |
| Ent. to Revenue | 2.78 | - | Cheaper |
| PE Ratio | 18.16 | 41.03 | Cheaper |
| Price to Book | 3.69 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 40.71 | - | Lower Risk |
| Debt to Equity | 0.41 | -1.23 | Expensive |
| Debt to Assets | 0.26 | 0.25 | Par |
| Market Cap | 1.99B | - | Emerging |
